who is Flinn ferguson | cresa
Flinn Ferguson is a corporate real estate services firm that specializes in complex lease negotiations designed to maximize economic considerations.
our services
Flinn Ferguson Cresa emphasizes listening to the client and offering all information and options needed to facilitate our clients’ decision-making processes.
Our Culture
Flinn Ferguson Cresa’s culture is like a family and all of our people sincerely care about each other and our clients. We regularly collaborate with and encourage one another, while avoiding the internal competition that is so common within our industry.
ethical standards
Flinn Ferguson Cresa’s mantra is ‘Do the Right Thing.’ When partnering with our clients we pride ourselves on complete transparency and offering advice with our clients best interests at heart, free from conflicts of interest.
Our Mission
Provide top quality, thoughtful, creative, and result-oriented services with integrity, professionalism and respect for our clients and the community while enjoying our professional lives.
Diversity and Inclusion
Flinn Ferguson Cresa and its DIB Committee members are committed to change. We acknowledge that our current workforce does not meet our own standards for diversity, nor does it accurately represent the communities in which our offices are located. To change this, we’ve established actionable goals to bring us into a more diverse and inclusive future.
our clients
Helping Companies Find Their Perfect Space
global partners
Cresa has partnered with Knight Frank’s Occupier Strategy & Solutions division to create the largest global platform focused exclusively on occupiers.
News
Market Report
Q1 2026 Industrial Market Report
Recent tariff driven shifts—particularly elevated U.S. tariffs on Chinese imports and ongoing policy uncertainty—have materially reduced container volumes through the Seattle–Tacoma gateway, with early 2026 data showing notable year-over-year declines following a 2025 pull-forward of imports.
Q1 2026 Life Science Market Report
Q1 2026 carried forward much of the cautious optimism that closed out the prior year, though early-stage activity remained constrained as investors continued to prioritize capital efficiency and later-stage (mostly clinical asset) opportunities.